[The antiretroviral agent Fullevir].
The antiretroviral properties of Fullevir (sodium salt of fullerenepolyhydropolyaminocaproic acid) manufactured by IntelFarm Co.) were studied in the human cell culture infected with human immunodeficiency virus (HIV). The agent was ascertained to be able to protect the cell from the cytopathic action of HIV. The 90% effective concentration (EF90) was 5 microg/ml. The 50% average toxic concentration was 400 microg/ml. Testing of different (preventive and therapeutic) Fullevir dosage regimens has shown that the drug is effective when used both an hour before and an hour after infection and when administered simultaneously with cell infection. The longer contact time for the agent with the cells increased the degree of antiviral defense. Co-administration of Fullevir and the HIV reverse transcriptase inhibitor Retrovir (azidothymidine) showed a synergistic antiretroviral effect. Thus, Fullevir may be regarded as a new promising antiretroviral drug for the treatment of HIV infection.
Nosik
D N
DN
Lialina
I K
IK
Kalnina
L B
LB
Lobach
O A
OA
Chataeva
M S
MS
Rasnetsov
L D
LD
D000614:Aminocaproates / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D037741:Fullerenes / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D015215:Zidovudine / Q000494:pharmacology
C540009:1-hydrofullereneaminocaproic acid, sodium salt; D000614:Aminocaproates; D019380:Anti-HIV Agents; D037741:Fullerenes; D015215:Zidovudine